Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.1%

Bicara Therapeutics Inc. (NASDAQ:BCAX)’s stock price dropped 6.1% during mid-day trading on Wednesday . The company traded as low as $22.70 and last traded at $22.93. Approximately 103,809 shares were traded during trading, a decline of 72% from the average daily volume of 376,747 shares. The stock had previously closed at $24.43.

Bicara Therapeutics Trading Down 3.7 %

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, Director Ra Capital Management, L.P. acquired 1,833,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was acquired at an average cost of $18.00 per share, with a total value of $32,994,000.00. Following the purchase, the director now directly owns 4,303,418 shares in the company, valued at approximately $77,461,524. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. In other Bicara Therapeutics news, major shareholder James E. Flynn purchased 70,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The shares were purchased at an average cost of $18.00 per share, with a total value of $1,260,000.00. Following the purchase, the insider now owns 897,587 shares in the company, valued at $16,156,566. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The shares were bought at an average cost of $18.00 per share, with a total value of $32,994,000.00. Following the transaction, the director now directly owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. The disclosure for this purchase can be found here.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.